Control and Risk Factors of Nausea and Vomiting in Patients With Cervical Cancer Receiving Radiotherapy.

インデックスリンク

インデックスツリー

RootNode

アイテム

Control and Risk Factors of Nausea and Vomiting in Patients With Cervical Cancer Receiving Radiotherapy.

https://gifu-pu.repo.nii.ac.jp/records/14838

Item type		研究室原著論文(1)
公開日		2023-03-17
タイトル
	タイトル	Control and Risk Factors of Nausea and Vomiting in Patients With Cervical Cancer Receiving Radiotherapy.
	言語	en
言語
	言語	eng
キーワード
	言語	en
	主題Scheme	Other
	主題	Antiemetics
キーワード
	言語	en
	主題Scheme	Other
	主題	Antineoplastic Agents
キーワード
	言語	en
	主題Scheme	Other
	主題	Cisplatin
キーワード
	言語	en
	主題Scheme	Other
	主題	Dexamethasone
キーワード
	言語	en
	主題Scheme	Other
	主題	Female
キーワード
	言語	en
	主題Scheme	Other
	主題	Humans
キーワード
	言語	en
	主題Scheme	Other
	主題	Nausea
キーワード
	言語	en
	主題Scheme	Other
	主題	Retrospective Studies
キーワード
	言語	en
	主題Scheme	Other
	主題	Risk Factors
キーワード
	言語	en
	主題Scheme	Other
	主題	Uterine Cervical Neoplasms
キーワード
	言語	en
	主題Scheme	Other
	主題	Vomiting
資源タイプ
	資源タイプ識別子	http://purl.org/coar/resource_type/c_6501
	資源タイプ	journal article
アクセス権
	アクセス権	metadata only access
	アクセス権URI	http://purl.org/coar/access_right/c_14cb
抄録
	値	Background/aim: Nausea and vomiting are two of the most distressing adverse events of cancer radiotherapy. The aim of this study was to examine the control rate and risk factors associated with nausea and vomiting in patients with cervical cancer receiving radiotherapy. Patients and methods: This retrospective study examined patients with cervical cancer who received radiotherapy alone or with concomitant cisplatin. Patients who received radiotherapy alone were not administered antiemetic premedication, while patients who received radiotherapy with concomitant weekly cisplatin (40 mg/m2) were administered antiemetic therapy comprising granisetron and dexamethasone. Risk factors for non-complete response (CR) were identified using multivariate logistic regression analysis. Results: Multivariate analysis indicated that younger age and concomitant weekly cisplatin were significant factors associated with non-CR across 5 weeks of treatment in patients who received radiotherapy. The proportion achieving CR among younger patients (<65 years) who received radiotherapy alone or with concomitant cisplatin was significantly lower than that among older patients (≥65 years) (Concomitant cisplatin: 27% vs. 67%, p=0.049; Radiotherapy alone: 62% vs. 91%, p=0.166). However, the proportion of patients achieving CR across 5 weeks of treatment was insufficient in all groups except for those aged ≥ 65 years who received radiotherapy alone. Conclusion: Antiemetic prophylaxis should be considered for younger patients with cervical cancer undergoing radiotherapy alone. Further, neurokinin-1 receptor antagonist should be added to 5-hydroxytryptamine type-3 receptor antagonist and dexamethasone as antiemetic prophylactic therapy for patients with cervical cancer undergoing radiotherapy with concomitant weekly doses of 40 mg/m2 cisplatin.
書誌情報		en : Anticancer research 巻 42, 号 6, p. 3117-3123, 発行日 2022-06
DOI
	値	10.21873/anticanres.15800